Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market study identifies that the growing number of fractioning units will be one of the primary factors for the primary immunodeficiency diseases treatment market growth. Fractionation separates the immunoglobulins and blood protein from plasma, which in turn, results in the development of immunoglobulins. Immunoglobulin therapy is useful in reducing the symptoms of autoimmune disease and a wide range of infections as they easily detect the microorganisms that are entering the body and assist the immune cells in neutralizing them. Technavio’s market analysts estimate that the market will grow steadily at a CAGR of more than 6% by 2021.
The development of immunoglobulin therapy for primary immunodeficiency diseases (PIDDs) is growing steadily and is impacting the primary immunodeficiency diseases treatment market worth. Plasma donors are paid to maintain and meet the demands of plasma-derived therapeutics. The provision of financial aid for plasma donors is identified as one of the key trends contributing towards the growth of the primary immunodeficiency diseases treatment market. Providing financial aid to the plasma donors will increase the number of donors available in the future, catering to the demand for plasma-derived therapeutics.
The primary immunodeficiency diseases treatment market is populated due to the presence of several established international and domestic players. Manufacturers in this market compete intensely in terms of factors such as advances in technology, increased inorganic growth strategies, and increase in the capacity of fractionating units. To remain competitive in the primary immunodeficiency symptoms treatment market, vendors are implementing strategies such as M&A, distribution partnerships, and pricing strategies. Advanced technologies are integrated in products to develop the product portfolio.
The leading vendors in the market are
The other prominent vendors in the market are Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.
Primary immunodeficiency diseases (PIDDs) impact the body’s immunity by producing limited or negligible immunoglobulins. Immunoglobulin therapy protects against several infections and reduces the autoimmune disease symptoms. This therapy is used to treat various PIDDs and is required throughout the lifetime.
The Americas, primarily the US, is witnessing a high investment in R&D and the healthcare segment. Factors such as improved treatment regimen, awareness about rare and fatal diseases, technological advancement, and increase in disease prevalence rate drives the market growth in the region. Also, the increasing focus on rare diseases is demanding for PIDD treatment drugs that is contributing towards the growth of the primary immunodeficiency diseases treatment market in the Americas.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Pipeline landscape
PART 07: Market segmentation by therapy
PART 08: Geographical segmentation
PART 09: Decision framework
PART 10: Drivers and challenges
PART 11: Market trends
PART 12: Vendor landscape
PART 13: Key vendor analysis
PART 14: Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.